Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have proven cardiovascular benefits, are recommended in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). Howeve...

Source: Cardiovascular Diabetology - November 20, 2023 Category: Cardiology Authors: Xi Tan, Yuanjie Liang, Jigar R. Rajpura, Larisa Yedigarova, Josh Noone, Lin Xie, Silvio Inzucchi and Adam de Havenon Tags: Research Source Type: research